Literature DB >> 15963124

Extracorporeal application of high-intensity focused ultrasound for prostatic tissue ablation.

Axel Häcker1, Kai Uwe Köhrmann, Walter Back, Oliver Kraut, Ernst Marlinghaus, Peter Alken, Maurice Stephan Michel.   

Abstract

OBJECTIVE: To investigate the efficacy and safety of extracorporeal prostatic tissue ablation using high-intensity focused ultrasound (HIFU) in vivo in animals, and in a clinical feasibility study in men, as this is an investigational minimally invasive treatment alternative for locally confined prostatic carcinoma, but may have significant side-effects. PATIENTS,
MATERIALS AND METHODS: Ultrasound (1.04 MHz excitation frequency) was generated by an extracorporeal cylindrical piezo-ceramic element and focused by a paraboloidal reflector to a focal size of 32 x 4 mm. The focal distance and aperture diameter were both 100 mm. HIFU was applied extracorporeally at different intensities and pulse duration (up to 6 s) to 11 dog prostates in vivo (median intensity 1192 W/cm2) and eight patients (median intensity 3278 W/cm2, range 2384-3576) under general anaesthesia. The lesions were assessed macroscopically and histologically after HIFU and any side-effects evaluated.
RESULTS: Thermoablation was feasible in vivo and in all patients. Macroscopic analysis and histology showed sharply demarcated coagulative necrosis. Side-effects, including skin and rectal burns, occurred only after transvesical application in the in vivo study. There were no side-effects in patients after perineal application.
CONCLUSION: Extracorporeal HIFU is technically feasible and induces sharply demarcated tissue damage in the prostate. From the early results of this phase 1 study, the perineal approach seems to be safe.

Entities:  

Mesh:

Year:  2005        PMID: 15963124     DOI: 10.1111/j.1464-410X.2005.05570.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  7 in total

1.  MRI-compatible positioning device for guiding a focused ultrasound system for transrectal treatment of prostate cancer.

Authors:  Christos Yiallouras; Nicos Mylonas; Christakis Damianou
Journal:  Int J Comput Assist Radiol Surg       Date:  2013-12-13       Impact factor: 2.924

2.  Acoustic access to the prostate for extracorporeal ultrasound ablation.

Authors:  Timothy L Hall; Christopher R Hempel; Brian J Sabb; William W Roberts
Journal:  J Endourol       Date:  2010-08-02       Impact factor: 2.942

3.  Correlation of contrast-enhanced MR images with the histopathology of minimally invasive thermal and cryoablation cancer treatments in normal dog prostates.

Authors:  D M Bouley; B Daniel; K Butts Pauly; E Liu; A Kinsey; W Nau; C J Diederich; G Sommer
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2007-02-08

4.  Intermediate-term effects of intracardiac communications created noninvasively by therapeutic ultrasound (histotripsy) in a porcine model.

Authors:  Gabe E Owens; Ryan M Miller; Sonal T Owens; Scott D Swanson; Kimberly Ives; Greg Ensing; David Gordon; Zhen Xu
Journal:  Pediatr Cardiol       Date:  2011-09-11       Impact factor: 1.655

5.  Therapeutic ultrasound to noninvasively create intracardiac communications in an intact animal model.

Authors:  Gabe E Owens; Ryan M Miller; Greg Ensing; Kimberly Ives; David Gordon; Achi Ludomirsky; Zhen Xu
Journal:  Catheter Cardiovasc Interv       Date:  2010-10-12       Impact factor: 2.692

6.  Histotripsy of the prostate: dose effects in a chronic canine model.

Authors:  Timothy L Hall; Christopher R Hempel; Kirk Wojno; Zhen Xu; Charles A Cain; William W Roberts
Journal:  Urology       Date:  2009-07-22       Impact factor: 2.649

7.  High-Intensity Focused Ultrasound (HIFU) in Uterine Fibroid Treatment: Review Study.

Authors:  Mustafa Z Mahmoud; Mohammed Alkhorayef; Khalid S Alzimami; Manal Saud Aljuhani; Abdelmoneim Sulieman
Journal:  Pol J Radiol       Date:  2014-10-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.